Leading the revolution in real-time
drug safety and monitoring

At Infusense, we believe the power of real-time clinical data saves lives. That’s why we pioneer novel biosensor technology that delivers immediate, accurate measurements for faster, more personalized care.

INFUSENSE - HemaSense, Biosensor Technology

About Our Technology:


HemaSense is a first-in-class, hand-held device (like a glucometer used for checking blood sugar) that can be used by physicians to measure drug levels directly from a drop of blood or saliva, without sample processing.

How We're Different

  • Places toxicity testing and therapeutic drug monitoring into the hands of physicians — no need to send a sample to the lab
  • Simplifies sample collecting using a drop of blood or saliva — no syringes, sample tubes, etc., required
  • Provides results within 5 minutes

Current Method:
2-5 Hours

2-5 Minutes

How It Works

Biosensors convert biochemical information into electronic signals. HemaSense has a patented coating that allows many drugs to pass directly to the sensor, while blocking plasma proteins and other blood components.

Once in the membrane, the drug is oxidized by the electrode and generates a current that is directly proportional to its concentration. This tells the doctor the level of drug present in patients’ blood or saliva—enabling real-time clinical decision-making in order to:

    • Ensure patient medication compliance
    • Detect potential drug toxicity for 20+ drugs, including fentanyl, tricyclic anti-depressants, antipsychotics, and others
    • Optimize medication dosing and therapeutic monitoring

Clinical Applications

Emergency Medicine: real-time detection and management of drug toxicity and accidental poisoning at immediate point-of-care.

Therapeutic Drug Monitoring: real-time testing and ongoing monitoring of drug levels to optimize medical decision-making for each patient.

Patent Technology

U.S. Patents

Canadian Patents

European Patent

Clinical Impact

The Challenge:

There are over 3 million Emergency Room visits annually related to drug poisoning. Fentanyl poisoning is the primary cause of the growing opioid crisis, the leading cause of death among Americans aged 18 to 45.

The Need:

There is a critical, unmet need to provide rapid results for fentanyl testing in the ER, at the point of contact. Currently, measuring drug levels and toxicity is time consuming, expensive, and requires many hours or days to obtain results from the laboratory.

Our Solution:

HemaSense has been described by physicians as “a game changer” in patient care—enabling rapid diagnosis of toxic drug overdoses and poisonings in minutes (not hours) and improving personalized medication dosing and monitoring for mental illness, epilepsy, and other conditions. It can be easily adopted to provide better care and save lives.

About Infusense

In 2012, Infusense launched and licensed the technology and patents for point-of-care drug detection from the University of Tennessee. In 2013, Infusense received a Department of Defense Small Business Innovation Research (SBIR) grant to apply its use to sedation and anesthesia.

In 2021, Infusense was awarded a prestigious National Science Foundation SBIR grant for rapid detection of drug toxicity and poisoning.

Leadership Team

Edward Chaum, PhD
Edward Chaum, MD, PhD
Founder and Chief Medical Officer
Dr. Chaum is the Margy Ann and J Donald M Gass Professor of Ophthalmology at Vanderbilt University Medical Center and a clinician scientist with 25 years of experience in translational biomedical engineering. He was the Principal Investigator on the DOD grants developing the Infusense technology and is a serial entrepreneur.
Eric Kriegstein, BA, MBA
Chief Executive Officer
Mr. Kriegstein has over 15 years of experience in corporate development, investment management and corporate strategy as an entrepreneur in the healthcare sector.
Marcin Guzinski, PhD
Marcin Guzinski, PhD
Director of Engineering
Dr. Guzinski has 20 years of experience in electrochemistry, chemical metrology, and the development of solid-state sensors.
Erno Linder, PhD
Erno Lindner, PhD
Technical Advisor

Dr. Lindner, the R. Eugene Smith Professor of Biomedical Engineering and Professor of Chemistry at the University of Memphis, is an internationally recognized expert in the development and application of clinical biosensors and is an elected member of the Hungarian Academy of Sciences.

Infusense technology is not yet FDA-approved for human use.
Scroll to Top